Tardio Jason's most recent trade in Immunic Inc was a trade of 660,000 Stock Appreciation Right done . Disclosure was reported to the exchange on July 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunic Inc | Jason Tardio | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2025 | 660,000 | 660,000 | - | - | Stock Appreciation Right | |
| Immunic Inc | Jason Tardio | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2025 | 660,000 | 660,000 | - | - | Stock Appreciation Right | |
| Immunic Inc | Jason Tardio | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2025 | 330,000 | 330,000 | - | - | Stock Appreciation Right | |
| Immunic Inc | Jason Tardio | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2025 | 330,000 | 330,000 | - | - | Stock Appreciation Right | |
| Immunic Inc | Jason Tardio | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2025 | 330,000 | 330,000 | - | - | Stock Appreciation Right | |
| Immunic Inc | Jason Tardio | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 598,500 | 598,500 | - | - | Stock Option | |
| Immunic Inc | Jason Tardio | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 595,000 | 595,000 | - | - | Stock Option | |
| Immunic Inc | Jason Tardio | President and COO | Purchase of securities on an exchange or from another person at price $ 0.79 per share. | 05 Jun 2025 | 12,512 | 12,512 (0%) | 0% | 0.8 | 9,884 | Common Stock |
| Immunic Inc | Jason Tardio | President and COO | Purchase of securities on an exchange or from another person at price $ 0.79 per share. | 05 Jun 2025 | 12,512 | 12,512 (0%) | 0% | 0.8 | 9,884 | Common Stock |
| Immunic Inc | Jason Tardio | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2024 | 157,500 | 157,500 | - | - | Stock Option | |
| Immunic Inc | Jason Tardio | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2024 | 500,000 | 500,000 | - | - | Stock Option | |
| Ovid Therapeutics Inc | Jason Tardio | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 168,750 | 168,750 | - | - | Stock Option (Right to Buy) | |
| Ovid Therapeutics Inc | Tardio Jason | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 28,125 | 28,125 (0%) | 0% | 0 | Common Stock | |
| Ovid Therapeutics Inc | Jason Tardio | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Ovid Therapeutics Inc | Jason Tardio | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.15 per share. | 12 Sep 2022 | 17,344 | 0 (0%) | 0% | 2.2 | 37,290 | Common Stock |
| Ovid Therapeutics Inc | Jason Tardio | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2022 | 87,498 | 87,498 | - | - | Stock Option (Right to Buy) | |
| Ovid Therapeutics Inc | Jason Tardio | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Ovid Therapeutics Inc | Jason Tardio | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Ovid Therapeutics Inc | Jason Tardio | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Ovid Therapeutics Inc | Jason Tardio | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2020 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) |